8-K: 10x Genomics Reports Mixed Q3 Results, Updates Full-Year Outlook

10x Genomics reported a slight revenue decrease in Q3 2024, alongside an improved gross margin and reduced operating expenses, while also lowering its full-year revenue guidance.

Summary

• 10x Genomics announced its financial results for the third quarter of 2024, with revenue of $151.7 million, a 1% decrease compared to the same period last year.
• The company's gross margin improved to 70% from 62% year-over-year, primarily due to a change in product mix.
• Operating expenses decreased by 22% to $147.9 million, driven by a reduction in research and development expenses.
• The operating loss was $41.5 million, a significant improvement from the $94.8 million loss in the prior year.
• Net loss for the quarter was $35.8 million, compared to a net loss of $93.0 million in the third quarter of 2023.
• 10x Genomics updated its full-year 2024 revenue guidance to a range of $595 million to $605 million, down from the previous range of $640 million to $660 million.
• This updated guidance represents a 3% decrease from the full year 2023 revenue at the midpoint.
• The company's cash and cash equivalents stood at $398.2 million as of September 30, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company showed improvements in gross margin and reduced operating expenses, the revenue decline and lowered guidance are concerning. The new product launches are a positive sign, but the overall outlook is mixed.

Positives

• Gross margin improved significantly to 70%, indicating better profitability on sales.
• Operating expenses decreased by 22%, showing improved cost management.
• The operating loss and net loss both improved substantially compared to the same quarter last year.
• The company launched new products like GEM-X Flex, GEM-X Universal Multiplex, and Chromium Xo, which could drive future growth.
• The company has a strong cash position with $398.2 million in cash and cash equivalents.

Negatives

• Revenue decreased by 1% year-over-year, indicating a slowdown in sales.
• The company lowered its full-year revenue guidance, suggesting weaker performance than previously expected.
• The company cited sales restructuring and cautious customer spending as reasons for the lower revenue.
• The updated revenue guidance represents a 3% decrease from the full year 2023 revenue at the midpoint.

Risks

• The company is experiencing disruption from a sales restructuring, which is impacting revenue.
• Cautious customer spending is contributing to lower-than-expected sales.
• The company is operating in a difficult macroeconomic environment, which could further impact its performance.
• The company's revenue growth for the year will be lower than previous expectations.

Future Outlook

10x Genomics has updated its full-year 2024 revenue guidance to a range of $595 million to $605 million, which is lower than the previous guidance of $640 million to $660 million. This updated range represents a 3% decrease from the full year 2023 revenue at the midpoint.

Management Comments

• Serge Saxonov, Co-founder and CEO, stated that the results fell short of expectations due to sales restructuring and cautious customer spending.
• Serge Saxonov expressed confidence that the steps being taken will enable the company to reach more customers and drive the broad democratization of their technologies.

Industry Context

The life science tools industry is facing headwinds due to cautious customer spending and macroeconomic uncertainty. 10x Genomics' results reflect these challenges, as seen in other companies in the sector. The launch of new products like GEM-X Flex and Chromium Xo is aimed at addressing cost concerns and expanding market reach.

Comparison to Industry Standards

• Competitors like Illumina and Bio-Rad have also reported mixed results recently, indicating a broader trend of slower growth in the life science tools sector.
• While 10x Genomics' gross margin improvement is positive, its revenue decline is concerning compared to some peers who have managed to maintain growth.
• The company's focus on cost-effective solutions like GEM-X Flex and Chromium Xo is a strategic move to compete with companies offering more budget-friendly options.
• The reduction in operating expenses is a positive sign, but the company needs to demonstrate consistent revenue growth to match industry leaders.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the lowered revenue guidance and the slight decrease in revenue.
• Employees may be affected by the sales restructuring and its impact on the company's performance.
• Customers may benefit from the new cost-effective products, but may also be cautious about spending due to the current economic environment.
• Suppliers may be impacted by changes in the company's sales and production volumes.

Next Steps

• The company will host a conference call to discuss the third quarter 2024 financial results, business developments and outlook.
• The company will continue to focus on executing its sales strategy and driving adoption of its new products.

Key Dates

Keywords

10x Genomics, single cell analysis, spatial biology, financial results, revenue, gross margin, operating expenses, net loss, GEM-X Flex, Chromium Xo, financial guidance